// App-Quantinova.ai

201 : Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient non-endometrial solid tumors: A post-hoc subgroup analysis of patients with colorectal cancer.

Researchers

Presenter

  • Thierry Andre

Principal Investigators

  • Filippo G. De Braud

  • Begona Jimenez-Rodriguez

  • Dominique Berton

  • Giuseppe Curigliano

  • Tobias Arkenau

  • Antonio Antn Torres

  • David Paez

  • Susan Ellard

  • Cyril Abdeddaim

  • Eduardo Castanon Alvarez

  • Francine Aubin

  • Tao Duan

  • Jennifer Taylor Veneris

  • Eleftherios Zografos

  • Naureen Starling

Medical Centers

  • Sorbonne Université, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, Paris, France

  • Medical Oncology Department, ENETS Center of Excellence, Fondazione IRCCS Istituto Nazionale dei Tumori and Oncology and Hemato-oncology Department, University of Milan, Milan, Italy

  • Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain

  • GINECO and Institut de Cancerologie de lOuest (ICO) Rene Gauducheau, Saint-Herblain, France

  • Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy

  • Sarah Cannon Research Institute, London, United Kingdom

  • Hospital Universitario Miguel Servet, Geicam Spanish Breast Cancer Group, Zaragoza, Spain

  • Hospital Santa Creu i Sant Pau, Barcelona, Spain

  • BC Cancer Agency, Kelowna, BC, Canada

  • Centre de Lutte Contre le Cancer-Centre Oscar Lambret, Lille, France

  • GEICO and Clinica Universitaria de Navarra, Madrid, Spain

  • Centre de Recherche du Centre Hospitalier de lUniversite de Montreal, Montreal, QC, Canada

  • GlaxoSmithKline, Pennington, NJ

  • GlaxoSmithKline, Waltham, MA

  • GlaxoSmithKline, London, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

Locations

  • France

  • Italy

  • Spain

  • United Kingdom

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Solid malignancies

Biomarkers

  • Microsatellite instability-high

Drug/Treatment

  • Oxaliplatin

  • Dostarlimab

  • Irinotecan

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Open Label

  • Single Arm

  • Multicenteric

  • Cohort

Phase

  • I

Study Id's

  • NCT02715284

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved